Literature DB >> 10613829

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

B Ramratnam1, J E Mittler, L Zhang, D Boden, A Hurley, F Fang, C A Macken, A S Perelson, M Markowitz, D D Ho.   

Abstract

Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment. Recent studies have identified resting, memory CD4+ T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses indicate that the reservoir is rather small, between 103 and 107 cells per patient. In individuals whose plasma viremia levels are well suppressed by anti-retroviral therapy, peripheral blood mononuclear cells containing replication-competent HIV-1 were found to decay with a mean half-life of approximately 6 months, close to the decay characteristics of memory lymphocytes in humans and monkeys. In contrast, little decay was found in a less-selective patient population. We undertook this study to address this apparent discrepancy. Using a quantitative micro-culture assay, we demonstrate here that the latent reservoir decays with a mean half-life of 6.3 months in patients who consistently maintain plasma HIV-1 RNA levels of fewer than 50 copies/ml. Slower decay rates occur in individuals who experience intermittent episodes of plasma viremia. Our findings indicate that the persistence of the latent reservoir of HIV-1 despite prolonged treatment is due not only to its slow intrinsic decay characteristics but also to the inability of current drug regimens to completely block HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613829     DOI: 10.1038/71577

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  167 in total

1.  Latency and viral persistence in HIV-1 infection.

Authors:  J D Siliciano; R F Siliciano
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

3.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

5.  Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection.

Authors:  Viktor Müller; Javier Flavio Vigueras-Gómez; Sebastian Bonhoeffer
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 6.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments.

Authors:  David C Nickle; Mark A Jensen; Daniel Shriner; Scott J Brodie; Lisa M Frenkel; John E Mittler; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

9.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

10.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.